Sagimet Biosciences announced that its license partner, Ascletis BioScience, will present 52-week results from a Phase 3 open-label extension trial of denifanstat for acne vulgaris in October 2026. This disclosure provides an update on the drug's long-term safety and efficacy, which could influence future regulatory and commercial prospects.
Sagimet Biosciences (SGMT) announced that its partner, Ascletis BioScience (1672.HK), will present 52-week Phase 3 data for denifanstat in acne vulgaris at a dermatology conference in October 2026. This is a positive development as it provides further long-term efficacy and safety data for a key pipeline asset. The NDA for denifanstat has already been accepted in China, indicating progress towards commercialization in that region. For Sagimet, this data could support its development efforts in other territories and potentially increase the drug's overall value. While the presentation is still over two years away, the pre-announcement of positive findings (significant improvements observed as early as 4 weeks and continued clinical improvements through 52 weeks) provides a positive signal for both companies, particularly Sagimet which holds rights outside of China. The long-term implications are positive for the drug's market potential, but the immediate market impact is moderate given the distant presentation date and the fact that the NDA acceptance in China was already known.